Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Burning Rock Biotech Limited is a diagnostics & research business based in the US. Burning Rock Biotech shares (BNR) are listed on the NASDAQ and all prices are listed in US Dollars. Burning Rock Biotech employs 938 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$13.18|
|52-week range||$14.92 - $39.75|
|50-day moving average||$18.33|
|200-day moving average||$25.10|
|Wall St. target price||$32.72|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.17|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-8.22%|
|1 month (2021-09-22)||-35.30%|
|3 months (2021-07-22)||-52.07%|
|6 months (2021-04-22)||-54.25%|
|1 year (2020-10-22)||-54.46%|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Revenue TTM||$489.5 million|
|Gross profit TTM||$313.9 million|
|Return on assets TTM||-14.91%|
|Return on equity TTM||-27.13%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 1.7 million Burning Rock Biotech shares held short by investors – that's known as Burning Rock Biotech's "short interest". This figure is 32% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Burning Rock Biotech shares can be evaluated.
Burning Rock Biotech's "short interest ratio" (SIR) is the quantity of Burning Rock Biotech shares currently shorted divided by the average quantity of Burning Rock Biotech shares traded daily (recently around 280818.13804173). Burning Rock Biotech's SIR currently stands at 6.23. In other words for every 100,000 Burning Rock Biotech shares traded daily on the market, roughly 6230 shares are currently held short.
However Burning Rock Biotech's short interest can also be evaluated against the total number of Burning Rock Biotech shares, or, against the total number of tradable Burning Rock Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Burning Rock Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Burning Rock Biotech shares in existence, roughly 20 shares are currently held short) or 0.0522% of the tradable shares (for every 100,000 tradable Burning Rock Biotech shares, roughly 52 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Burning Rock Biotech.
Find out more about how you can short Burning Rock Biotech stock.
We're not expecting Burning Rock Biotech to pay a dividend over the next 12 months.
Burning Rock Biotech's shares were split on a 1:3 basis on 31 July 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Burning Rock Biotech shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Burning Rock Biotech shares which in turn could have impacted Burning Rock Biotech's share price.
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.